References
- 1. E. R. Rayburn, S. J. Ezell and R. Zhang, Anti-inflammatory agents for cancer therapy, Mol. Cell. Pharmacol.1 (2009) 29–43; https://doi.org/10.4255/mcpharmacol.09.05
- 2. M. J. Thun, S. J. Henley and C. Patrono, Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues, J. Natl. Cancer Inst.94 (2002) 252–266; https://doi.org/10.1093/jnci/94.4.252
- 3. S. R. Pedada, N. S. Yarla, P. J. Tambade, B. L. Dhananjaya, A. Bishayee, K. M. Arunasree, G. H. Philip, G. Dharmapuri, G. Aliev, S. Putta and G. Rangaiah, Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents, Eur. J. Med. Chem.112 (2016) 289–297; https://doi.org/10.1016/j.ejmech.2016.02.025
- 4. C. Sobolewski, C. Cerella, M. Dicato, L. Ghibelli and M. Diederich, The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies, Int. J. Cell Biol.2010 (2010) 1–21; https://doi.org/10.1155/2010/215158
- 5. C. S. Williams, M. Mann and R. N. DuBois, The role of cyclooxygenases in inflammation, cancer, and development, Oncogene18 (1999) 7908–7916; https://doi.org/10.1038/sj.onc.1203286
- 6. C. Ruegg, J. Zaric and R. Stupp, Non-steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality, Ann. Med.35 (2003) 476–487; https://doi.org/10.1080/07853890310017053
- 7. A. T. Koki and J. L. Masferrer, Celecoxib: a specific COX-2 inhibitor with anticancer properties, Cancer Control9 (2002) 28–35; https://doi.org/10.1177/107327480200902S04
- 8. A. M. Gouda and A. H. Abdelazeem, An integrated overview on pyrrolizines as potential anti-inflammatory, analgesic and antipyretic agents, Eur. J. Med. Chem.114 (2016) 257–292; https://doi.org/10.1016/j.ejmech.2016.01.055
- 9. A. M. Gouda, A. H. Abdelazeem, H. A. Omar, A. N. Abdalla, M. A. S. Abourehab and H. I. Ali, Pyrrolizines: design, synthesis, anticancer evaluation and investigation of the potential mechanism of action, Bioorg. Med. Chem. 25 (2017) 5637–5651; https://doi.org/10.1016/j.bmc.2017.08.039 (in press)
- 10. A. M. Gouda, H. I. Ali, W. H. Almalki, M. A. Azim, M. A. S. Abourehab and A. H. Abdelazeem, Design, synthesis, and biological evaluation of some novel pyrrolizine derivatives as COX inhibitors with anti-inflammatory/analgesic activities and low ulcerogenic liability, Molecules21 (2016) 1–21; https://doi.org/10.3390/molecules21020201
- 11. J.-P. Raynauld, J. Martel-Pelletier, P. Bias, S. Laufer, B. Haraoui, D. Choquette, A. D. Beaulieu, F. Abram, M. Dorais, E. Vignon and J.-P. Pelletier, Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI, Ann. Rheum. Dis.68 (2009) 938–947; https://doi.org/10.1136/ard.2008.088732
- 12. W. Liu, J. Zhou, K. Bensdorf, H. Zhang, H. Liu, Y. Wang, H. Qian, Y. Zhang, A. Wellner, G. Rubner, W. Huang, C. Guo and R. Gust, Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives, Eur. J. Med. Chem.46 (2011) 907–913; https://doi.org/10.1016/j.ejmech.2011.01.002
- 13. S. Tavolari, M. Bonafe, M. Marini, C. Ferreri, G. Bartolini, E. Brighenti, S. Manara, V. Tomasi, S. Laufer and T. Guarnieri, Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade, Carcinogenesis29 (2008) 371–380; https://doi.org/10.1093/carcin/bgm265
- 14. S. Tavolari, A. Munarini, G. Storci, S. Laufer, P. Chieco and T. Guarnieri, The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells, Cancer Lett.321 (2012) 187–194; https://doi.org/10.1016/j.canlet.2012.02.003
- 15. V. Lisowski, C. Enguehard, J. Lancelot, D. Caignard, S. Lambel, S. Leonce, A. Pierre, G. Atassi, P. Renard and S. Rault, Design, synthesis and antiproliferative activity of tripentones: a new series of antitubulin agents, Bioorg. Med. Chem. Lett.11 (2001) 2205–2208; https://doi.org/10.1016/S0960-894X(01)00403-6
- 16. V. Lisowski, S. Leonce, L. Kraus-Berthier, J. Sopkova-de Oliveira Santos, A. Pierre, G. Atassi, D.-H. Caignard, P. Renard and S. Rault, Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents, J. Med. Chem.47 (2004) 1448–1464; https://doi.org/10.1021/jm030961z
- 17. C. Rochais, T. Cresteil, V. Perri, M. Jouanne, A. Lesnard, S. Rault and P. Dallemagne, MR22388, a novel anti-cancer agent with a strong FLT-3 ITD kinase affinity, Cancer Lett.331 (2013) 92–98; https://doi.org/10.1016/j.canlet.2012.12.017
- 18. A. M. Gouda, A. H. Abdelazeem, E.-S. A. Arafa and K. R. A. Abdellatif, Design, synthesis and pharmacological evaluation of novel pyrrolizine derivatives as potential anticancer agents, Bioorg. Chem.53 (2014) 1–7; https://doi.org/10.1016/j.bioorg.2014.01.001
- 19. A. Etienne and Y. Correia, Derivatives of 2-pyrrolidone, Bull. Soc. Chem.10 (1969) 3704–3712.
- 20. W. A. Jacobs and M. Heidelberger, The ferrous sulfate and ammonia method for the reduction of nitro to amino compounds, J. Am. Chem. Soc.39 (1917) 1435–1439; https://doi.org/10.1021/ja02252a017
- 21. M. Y. Ebeid, S. M. El-Moghazy, M. M. Hanna, F. A. Romeih and F. F. Barsoum, Synthesis and anti-HIV activity of some 6,7-dihydro-5H-pyrrolizine-3-carboxamide, 5,6,7,8-tetrahydroindolizine-3-carboxamide, 1-thioxo-1,2,3,5,6,7,8,9,10,11-decahydro-pyrimido-[1,6-a]azonine-4-carbonitrile and 6-thioxo-1,2,5,6,8,9,10,11,12,13,14,14a-dodecahydro-pyrimido[4ʹ,5ʹ:4,5]pyrimido-[1,6-a]azonine-1-one derivatives, Bull. Fac. Pharm. Cairo Univ.35 (1997) 171–183.
- 22. C. A. Winter, E. A. Risley and G. W. Nuss, Carrageenan induced edema in hind paw of the rats as an assay for anti-inflammatory drugs, Proc. Soc. Exp. Biol. Med.111 (1962) 544–547; https://doi.org/10.3181/00379727-111-27849
- 23. A. Mollica, R. Costante, A. Stefanucci, F. Pinnen, G. Lucente, S. Fidanza and S. Pieretti, Novel cyclic biphalin analogue with improved antinociceptive properties, J. Pept. Sci.19 (2013) 233–239; https://pubs.acs.org/doi/10.1021/ml500241n
- 24. N. Handler, W. Jaeger, H. Puschacher, K. Leisser and T. Erker, Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors, Chem. Pharm. Bull. (Tokyo) 55 (2007) 64–71; https://doi.org/10.1248/cpb.55.64
- 25. E.-S. A. Arafa, A. H. Abdelazeem, H. H. Arab and H. A. Omar, OSU-CG5, a novel energy restriction mimetic agent, targets human colorectal cancer cells in vitro, Acta Pharmacol. Sin.35 (2014) 394–400; https://doi.org/10.1038/aps.2013.183
- 26. I. Vermes, C. Haanen, H. Steffens-Nakken and C. Reutellingsperger, A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V, J. Immunol. Methods184 (1995) 39–51; https://doi.org/10.1016/0022-1759(95)00072-I
- 27. C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv.Rev.23 (1997) 3–25; https://doi.org/10.1016/S0169-409X(96)00423-1
- 28. A. Daina, O. Michielin and V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep.7 (2017) Article ID 42717; https://doi.org/10.1038/srep42717
- 29. B. S. Selinsky, K. Gupta, C. T. Sharkey and P. J. Loll, Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations, Biochemistry40 (2001) 5172–5180; https://doi.org/10.1021/bi010045s
- 30. R. G. Kurumbail, A. M. Stevens, J. K. Gierse, J. J. McDonald, R. A. Stegeman, J. Y. Pak, D. Gildehaus, J. M. Miyashiro, T. D. Penning, K. Seibert, P. C. Isakson and W. C. Stallings, Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature384 (1996) 644–648; https://doi.org/10.1038/384644a0